We are live on ! Find out more
NAUT icon

Nautilus Biotechnolgy

86 hedge funds and large institutions have $120M invested in Nautilus Biotechnolgy in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

4% more funds holding

Funds holding: 8386 (+3)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

0.92% less ownership

Funds ownership: 46.2%45.28% (-0.92%)

13% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 23

23% less capital invested

Capital invested by funds: $155M → $120M (-$35M)

Holders
86
Holders Change
+3
Holders Change %
+3.61%
% of All Funds
1.48%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
11
Increased
20
Reduced
23
Closed
8
Calls
$9K
Puts
Net Calls
+$9K
Net Calls Change
-$26K

NAUT Hedge Fund Activity: Q3 2022 in Review

86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2022, worth a combined $120M — down 23% from $155M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NAUT positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 23 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $448K. The largest seller was RTW Investments, cutting an estimated $1.26M.

  • 86 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2022, up from 83 in Q2 2022.
  • Funds reported $120M of Nautilus Biotechnolgy stock for Q3 2022, down 23% quarter-over-quarter.
  • 11 funds opened new Nautilus Biotechnolgy positions in Q3 2022 and 8 closed out, a net change of +3 holders.
  • The largest Nautilus Biotechnolgy buyer in Q3 2022 was Morgan Stanley, an estimated $448K added.
  • The largest Nautilus Biotechnolgy seller in Q3 2022 was RTW Investments, an estimated $1.26M sold.

Based on aggregated 13F filings for Q3 2022.